BiomX

BiomX

BiomX is a biotechnology company developing phage therapies for eradicating bacteria associated with chronic diseases.

BiomX is a biotechnology company developing phage therapies for eradicating bacteria associated with chronic diseases that is headquartered in Ness Ziona, Israel and was founded in 2015 by Eran Elinav, Rotem Sorek, Timothy K. Lu, and Timothy Lu.

Funding

Series A

On May 15, 2017 BiomX completed their series A funding round with $24 million in funding from Takeda Ventures (lead investor), OrbiMed (lead investor), Johnson & Johnson Innovation (lead investor), Seventure Partners, SBI Japan-Israel Innovation Fund, and Mirae Asset Financial Group.

Series B

On February 20, 2019 BiomX completed their series A funding round with $32 million in funding from Seventure Partners (lead investor), RM Global Partners (lead investor), Takeda Ventures, SBI Japan-Israel Innovation Fund, OrbiMed, KB Investment, Johnson & Johnson Innovation, Handok, Consensus Business Group, and Chong Kun Dang Pharmaceutical Corp.

Timeline

February 2019

BiomX raises a $32,000,000 series B round from MiraeAsset, 8VC, RM Global Partners, OrbiMed, Seventure Partners, Johnson & Johnson Innovation – JJDC, Mirae Asset Financial Group, Takeda Ventures and Johnson & Johnson.

May 2017

BiomX raises a $24,000,000 series A round from SBI Japan-Israel Innovation Fund, Johnson & Johnson Innovation, Mirae Asset Venture Investment, OrbiMed, Seventure Partners and Takeda Ventures.

2015

BiomX was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.